Impact of adiposity and plasma adipocytokines on diabetic angiopathies in Japanese Type 2 diabetic subjects

Diabetic Medicine

Volumn 21, Issue 8, 2004, Pages 881-888

  Matsuda, M ^a   Kawasaki, F ^a   Yamada, K ^a   Kanda, Y ^a   Saito, M ^a   Eto, M ^a   Matsuki, M ^a   Kaku, K ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

Adipocytokines; Diabetic macroangiopathy; Diabetic microangiopathy; Fat localization

Indexed keywords

ADIPONECTIN; ALBUMIN; ALPHA GLUCOSIDASE INHIBITOR; CYTOKINE; INSULIN; LEPTIN; LIPID; METFORMIN; RESISTIN; SULFONYLUREA; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL RADIOGRAPHY; ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; ASIAN AMERICAN; BODY FAT; BODY MASS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIABETIC ANGIOPATHY; DIABETIC MICROANGIOPATHY; ECHOGRAPHY; EYE FUNDUS; FEMALE; HUMAN; INSULIN TREATMENT; KIDNEY DISEASE; LIPID BLOOD LEVEL; LIPID STORAGE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PROTEIN BLOOD LEVEL; PROTEINURIA; RETINOPATHY; SUBCUTANEOUS FAT; TISSUE DISTRIBUTION; URINARY EXCRETION;

ADIPOCYTES; ADIPONECTIN; ADIPOSE TISSUE; BODY MASS INDEX; CYTOKINES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DIABETIC RETINOPATHY; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIPIDS; MALE; MIDDLE AGED;

EID: 3843111317     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2004.01261.x     Document Type: Article

References (28)

1. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-359.
2. Matsuzawa Y, Funahashi T, Nakamura T. Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocyte-derived bioactive substances. Ann NY Acad Sci 1999; 892: 146-154.
3. Funahashi T, Nakamura T, Shimomura I, Maeda K, Kuriyama H, Takahashi M et al. Role of adipocytokines on the pathogenesis of atherosclerosis in visceral obesity. Intern Med 1999; 38: 202-206.
4. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochetn Biophys Res Commun 1999; 257: 79-83.
5. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20: 1595-1599.
6. Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, Parlongo S et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 2002; 13: 134-141.
7. Hotamisligil GS, Budavari A, Murray D, Spiegelman BM. Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha. J Clin Invest 1994; 94: 1543-1549.
8. Paquot N, Castillo MJ, Lefebvre PJ, Scheen AJ. No increased insulin sensitivity after a single intravenous administration of a recombinant human tumor necrosis factor receptor: Fc fusion protein in obese insulin-resistant patients. J Clin Endocrinol Metab 2000; 85: 1316-1319.
9. Ofei F, Hurel S, Newkirk J, Sopwith M, Taylor R. Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 1996; 45: 881-885.
10. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM et al. The hormone resistin links obesity to diabetes. Nature 2001; 409: 307-312.
11. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173-194.
12. World Health Organization. Report of a WHO Consultation, Part 1: Diagnosis and Classification of Diabetes Mellutis. WHO/NCD/NCS/99.2. Geneva: World Health Organization, 1999.
13. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
14. Aiello LP, Gardner TW, King GL, Blankenship G, Cavallerano JD, Ferris FL et al. Diabetic retinopathy. Diabetes Care 1998; 21: 143-156.
15. Yamasaki Y, Kodama M, Nishizawa H, Sakamoto K, Matsuhisa M, Kajimoto Y et al. Carotid intima-media thickness in Japanese type 2 diabetic subjects: predictors of progression and relationship with incident coronary heart disease. Diabetes Care 2000; 23: 1310-1315.
16. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999; 22: 1462-1470.
17. Ashwell M, Cole TJ, Dixon AK. Obesity: new insight into the anthropometric classification of fat distribution shown by computed tomography. Br Med J 1985; 290: 1692-1694.
18. Mitsuhashi N, Takayanagi N, Onuma T, Honda M, Kubo S, Kawamori R. Coronary artery disease and carotid artery intimamedia thickness in Japanese type 2 diabetic patients. Diabetes Care 2002; 25: 1308-1312,
19. Pignoli P, Tremoli E, Poli A, Oreste P, Paoletti R. Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation 1986; 74: 1399-1406.
20. Hirose H, Kawai T, Yamamoto Y, Taniyama M, Tomita M, Matsubara K et al. Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes. Metabolism 2002; 51: 314-317.
21. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001; 50: 2094-2099.
22. DeFronzo RA. Glucose intolerance and aging. Diabetes Care 1981; 4: 493-501,
23. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86: 1930-1935.
24. Bjorntorp P. Portal adipose tissue as a generator of risk factors for cardiovascular disease and diabetes. Arteriosclerosis 1990; 10: 493-496.
25. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001; 7: 941-946.
26. Tayama K, Inukai T, Shimomura Y. Preperitoneal fat deposition estimated by ultrasonography in patients with non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 1999; 43: 49-58.
27. Asakawa H, Tkunaga K, Kawakami F. Relationship of leptin level with metabolic disorders and hypertension in Japanese type 2 diabetes mellitus patients. J Diabetes Complications 2001; 15; 57-62.
28. Pellme F, Smith U, Funahashi T, Matsuzawa Y, Brekke H, Wiklund O et al. Circulating adiponectin levels are reduced in nonobese but insulin-resistant first-degree relatives of type 2 diabetic patients. Diabetes 2003; 52: 1182-1186.